22 results match your criteria: "and Tohoku University Graduate School of Medicine[Affiliation]"
Monoclon Antib Immunodiagn Immunother
April 2023
Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
We recently developed a novel anti-human C-C chemokine receptor 9 (hCCR9) monoclonal antibody (mAb), CMab-11, which is applicable to flow cytometry, western blotting, and enzyme-linked immunosorbent assay (ELISA). This study aims to identify the binding epitope of CMab-11 by using 1 × and 2 × alanine (or glycine) substituted-hCCR9 peptides (1 × and 2 × Ala-scan) by ELISA. According to the 1 × Ala-scan analysis, the response of CMab-11 was diminished against M13A of the hCCR9 peptide, but was not eliminated.
View Article and Find Full Text PDFMonoclon Antib Immunodiagn Immunother
April 2023
Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
One of G protein-coupled receptors, CC chemokine receptor 3 (CCR3), is expressed in eosinophils, basophils, a subset of Th2 lymphocytes, mast cells, and airway epithelial cells. CCR3 levels in the serum of colorectal cancer patients are significantly higher than in control groups. Moreover, CCR3 is essential for recruiting eosinophils into the lung.
View Article and Find Full Text PDFN Engl J Med
January 2023
From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) - both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana-Farber Cancer Institute (T.A.A.) - both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard, Lyon (P.A.C.) - both in France; the University of Manchester and the Christie NHS Foundation Trust, Manchester (J.W.V.), and University College London Cancer Institute, London (J.A.B.) - both in the United Kingdom; National Cancer Center Hospital, Tokyo (C.M.), Kanagawa Cancer Center, Yokohama (J.F.), Hokkaido University Hospital Cancer Center, Sapporo (Y.K.), and Tohoku University Graduate School of Medicine, Sendai (K.M.) - all in Japan; the Hospital of the University of Pennsylvania (T.B.K.) and Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital (E.P.M.) - both in Philadelphia; Amsterdam University Medical Center, University of Amsterdam, Amsterdam (H.-J.K.); Asan Medical Center, University of Ulsan College of Medicine (H.-M.C.), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (D.-Y.O.) - both in Seoul, South Korea; the National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan (L.-T.C.); Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology, University of Vic-Central University of Catalonia, Baselga Oncologic Institute, Hospital Quiron, Barcelona (J.T.); Mayo Clinic, Rochester, MN (A.M.); Johannes Gutenberg-Mainz University Medical Center, Mainz, Germany (M.M.); Mayo Clinic, Phoenix, AZ (D.A.); Epstein Health, Woodcliff Lake, NJ (R.S.E.); Taiho Oncology, Princeton, NJ (A.-B.H., T.S., V.W., Y.H., M.L., K.A.B.); and Ilumina, San Diego, CA (Y.F.).
Background: Alterations in fibroblast growth factor receptor 2 () have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis. Futibatinib, a next-generation, covalently binding FGFR1-4 inhibitor, has been shown to have both antitumor activity in patients with -altered tumors and strong preclinical activity against acquired resistance mutations associated with ATP-competitive FGFR inhibitors.
Methods: In this multinational, open-label, single-group, phase 2 study, we enrolled patients with unresectable or metastatic fusion-positive or rearrangement-positive intrahepatic cholangiocarcinoma and disease progression after one or more previous lines of systemic therapy (excluding FGFR inhibitors).
Monoclon Antib Immunodiagn Immunother
October 2022
Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Immune checkpoint molecules have received attention as targets of cancer immunotherapy. Killer cell lectin-like receptor subfamily G member 1 (KLRG1) is one of the immune checkpoint molecules expressed in CD4 T, CD8 T, and natural killer (NK) cells. KLRG1 exhibits antiviral and antitumor immunity, and its expression in T and NK cells is upregulated by viral infectious diseases and some tumors.
View Article and Find Full Text PDFMonoclon Antib Immunodiagn Immunother
October 2022
Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
CC chemokine receptor type-2 (CCR2) belongs to the G protein-coupled receptors superfamily, and is localized on cell surface of tumor cells and some immune cells, including monocytes and macrophages. CCR2 is a receptor for monocyte chemoattractant protein-1/C-C motif chemokine 2, and is involved in the progression of various diseases such as cancers. Therefore, the development of CCR2-targeted monoclonal antibody (mAb) is desired.
View Article and Find Full Text PDFMonoclon Antib Immunodiagn Immunother
August 2022
Department of Molecular Pharmacology and Tohoku University Graduate School of Medicine, Sendai, Japan.
Podoplanin (PDPN) is an essential marker of lung type I alveolar cells, kidney podocytes, and lymphatic endothelial cells. Monoclonal antibodies (mAbs) that can specifically recognize PDPN in immunohistochemistry are important to analyze the development of tissues and the pathogenesis of diseases, including cancers. We have developed anti-PDPN mAbs against many animal species; however, mAbs that can recognize elephant-derived membrane proteins and distinguish the specific cell types in immunohistochemistry are limited.
View Article and Find Full Text PDFMonoclon Antib Immunodiagn Immunother
June 2022
Department of Molecular Pharmacology and Tohoku University Graduate School of Medicine, Sendai, Japan.
The CXC chemokine receptor 6 (CXCR6) is a member of the G protein-coupled receptor family that is highly expressed in helper T type 1 cells, natural killer cells, cytotoxic T lymphocytes, and various type of cells in tumor microenvironment (TME). CXCR6 has been proposed as a therapeutic target against tumors through regulation of the tumor TME. In this study, we developed specific and sensitive monoclonal antibodies (mAbs) for mouse CXCR6 (mCXCR6), which are useful for flow cytometry and Western blotting by N-terminal peptide immunization into rat.
View Article and Find Full Text PDFMonoclon Antib Immunodiagn Immunother
June 2022
Department of Molecular Pharmacology and Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is one of the immune checkpoint molecules. TIGIT is expressed in T or natural killer (NK) cells and is upregulated in several cancers. Because TIGIT suppresses the antitumor activity of the T or NK cells by binding to its ligand, such as CD155, CD112, and CD113, TIGIT can be a molecular marker or a therapeutic target for cancer immunotherapy.
View Article and Find Full Text PDFMonoclon Antib Immunodiagn Immunother
June 2022
Department of Molecular Pharmacology and Tohoku University Graduate School of Medicine, Sendai, Japan.
Chinese hamster () and golden hamster () are important animal models of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, which affect several organs, including respiratory tract, lung, and kidney. Podoplanin (PDPN) is a marker of lung type I alveolar cells, kidney podocytes, and lymphatic endothelial cells. The development of anti-PDPN monoclonal antibodies (mAbs) for these animals is essential to evaluate the pathogenesis by SARS-CoV-2 infections.
View Article and Find Full Text PDFMonoclon Antib Immunodiagn Immunother
June 2022
Department of Antibody Drug Development and Tohoku University Graduate School of Medicine, Sendai, Japan.
CC chemokine receptor type-2 (CCR2) belongs to the G protein-coupled receptors superfamily, localized on cell surface of some immune-related cells, including monocytes and macrophages. CCR2 and its ligand CCL2 are involved in the progression of various diseases such as cancers. Therefore, CCR2-targeted monoclonal antibodies (mAbs) are needed for treatment and diagnosis.
View Article and Find Full Text PDFInt J Epidemiol
January 2022
MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, UK.
Monoclon Antib Immunodiagn Immunother
December 2021
Department of Anatomy and Cell Biology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Diacylglycerol kinase (DGK) is a lipid kinase that converts diacylglycerol (DG) to phosphatidic acid (PA). Since both DG and PA serve as intracellular second messenger molecules, DGK plays a pivotal role in balancing these two signaling pathways. Of the DGK family, DGKη is classified as a type II DGK.
View Article and Find Full Text PDFMonoclon Antib Immunodiagn Immunother
December 2021
Department of Antibody Drug Development and Tohoku University Graduate School of Medicine, Sendai, Japan.
CD20 is one of the B-lymphocyte antigens and an effective target for the detection and treatment of B cell lymphomas; specific and sensitive monoclonal antibodies (mAbs) are required thus for their diagnosis. Recently, we developed a novel anti-CD20 mAb (clone CMab-60), which is not only useful for flow cytometry but also for Western blot and immunohistochemical analyses. However, the epitope of CMab-60 has not been determined.
View Article and Find Full Text PDFMonoclon Antib Immunodiagn Immunother
December 2021
Department of Antibody Drug Development and Tohoku University Graduate School of Medicine, Sendai, Japan.
One of G protein-coupled receptors, CCR9, is mainly expressed in the thymocytes and the small bowel. The ligand of CCR9 is CCL25 (TECK), and the CCR9-CCL25 axis controls T cell maturation and intestinal immune response. CCR9 is related to graft-versus-host disease and autoimmune diseases.
View Article and Find Full Text PDFMonoclon Antib Immunodiagn Immunother
December 2021
Department of Antibody Drug Development and Tohoku University Graduate School of Medicine, Sendai, Japan.
Human epidermal growth factor receptor 2 (HER2) is a type I transmembrane 185 kDa protein expressed in various types of normal or cancer cells. Overexpression of HER2 is found in many cancers and is related to cell proliferation, differentiation, and migration. We recently developed a novel anti-HER2 monoclonal antibody, HMab-181, by immunizing mice with the purified recombinant extracellular domain of HER2.
View Article and Find Full Text PDFMonoclon Antib Immunodiagn Immunother
December 2021
Department of Antibody Drug Development and Tohoku University Graduate School of Medicine, Sendai, Japan.
CD20 is a glycosylated transmembrane protein and is expressed on normal B cells and B cell malignancies. Therapeutic antibodies against CD20 are developed and used in clinic. The understanding of antibody-antigen binding by revealing the epitope is essential for future application to antibody technology.
View Article and Find Full Text PDFMonoclon Antib Immunodiagn Immunother
October 2021
Department of Antibody Drug Development, and Tohoku University Graduate School of Medicine, Sendai, Japan.
CD44 is a type I transmembrane protein expressed in various kinds of normal cancer cells, including pancreatic, breast, and oral cancers. CD44 is associated with cancer progression, metastases, and treatment resistance. CD44 consists of 20 exons, and various isoforms exist due to alternative splicing of the central 10 exons.
View Article and Find Full Text PDFMonoclon Antib Immunodiagn Immunother
October 2021
Department of Antibody Drug Development and Tohoku University Graduate School of Medicine, Sendai, Japan.
Podocalyxin (PODXL) is a type I transmembrane sialoglycoprotein that is overexpressed in human cancers, including breast, oral, and lung. PODXL promotes tumor progression, and its expression is associated with poor prognosis. Since PODXL is expressed in normal cells, including kidney podocytes and vascular endothelial cells (VECs), cancer-specific monoclonal antibodies (mAbs) are necessary to reduce the adverse effects of antibody therapy on PODXL-expressing cancers.
View Article and Find Full Text PDFBreastfeed Med
May 2021
Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.
Evaluation of the safety of taking lamotrigine (LTG) during lactation in breastfed infants varies according to the information sources. As it is possible that prescribers may avoid prescribing LTG despite of it being one of the essential drugs, more information needs to be accumulated to facilitate its use. We retrospectively compared the safety of LTG during the lactation period in 20 pairs of mothers and infants with 20 pairs as the control group.
View Article and Find Full Text PDFArthritis Rheumatol
April 2020
Osaki Citizen Hospital Osaki, Japan and Tohoku University Graduate School of Medicine, Sendai, Japan.
Arthritis Rheumatol
November 2014
University of Southampton Medical School, Southampton, UK, and Tohoku University Graduate School of Medicine, Sendai, Japan.
Objective: To investigate whether the changes in collagen gene expression in osteoarthritic (OA) human chondrocytes are associated with changes in the DNA methylation status in the COL2A1 enhancer and COL9A1 promoter.
Methods: Expression levels were determined using quantitative reverse transcription-polymerase chain reaction, and the percentage of DNA methylation was quantified by pyrosequencing. The effect of CpG methylation on COL9A1 promoter activity was determined using a CpG-free vector; cotransfections with expression vectors encoding SOX9, hypoxia-inducible factor 1α (HIF-1α), and HIF-2α were carried out to analyze COL9A1 promoter activities in response to changes in the methylation status.
J Neurosurg
July 2012
Department of Neurosurgery, Kohnan Hospital, and Tohoku University Graduate School of Medicine, Miyagi, Japan.
Object: In this paper, the authors' goals were to clarify the characteristics of growing unruptured cerebral aneurysms detected by serial MR angiography and to establish the recommended follow-up interval.
Methods: A total of 1002 patients with 1325 unruptured cerebral aneurysms were retrospectively identified. These patients had undergone follow-up evaluation at least twice.